Koi Peptides releases 2026 peptide industry report as market nears $140B

Koi Peptides published a 2026 industry report compiling 26 sourced data points on peptide market growth, FDA approvals and quality issues in research-use-only supply. The company says the report is meant to help labs and buyers evaluate a market split between regulated medicines and unapproved research materials.

Why it matters: - The peptide market is growing fast, but the gap between FDA-approved medicines and research-grade supply is widening. - The report argues that sourcing quality now affects both research reliability and buyer risk in a market approaching $140 billion. - The company positions the report as a reference for laboratories, contract research organizations and other buyers making sourcing decisions.

What happened: - Koi Peptides released its 2026 Peptide Industry Report on June 17, 2026. - Koi Research Labs LLC, which runs the Koi Peptides brand, compiled 26 sourced data points in a single document. - The report covers market size, drug approvals, clinical efficacy, safety, immunogenicity and product quality. - The full report is available as the company’s announcement.

The details: - The report says the global peptide therapeutics market was worth $140.86 billion in 2025 and is projected to reach $294.58 billion by 2033, according to Grand View Research. - More than 80 peptide drugs hold FDA approval and generate roughly $50 billion in annual revenue, according to a 2025 ScienceDirect review. - More than 150 peptide candidates are in clinical trials, with another 600 to 700 in preclinical development. - North America accounts for close to 62% of the global market. - GLP-1 medicines for diabetes and obesity drive most of the market’s growth. - About 3,940 antimicrobial peptides are cataloged, but fewer than 10 hold FDA approval. - In the SURMOUNT-5 trial published in the New England Journal of Medicine, tirzepatide reduced body weight by 20.2% versus 13.7% for semaglutide over 72 weeks. - Eli Lilly committed more than $6 billion to a new manufacturing plant in Huntsville, Alabama, announced in late 2025. - Novo Nordisk held more than 17% of the market in 2024. - Fortune Business Insights projects the market will reach $334.95 billion by 2034, with estimates varying by category definition.

Between the lines: - The report draws a sharp line between approved peptide medicines and research-grade peptides sold for laboratory study only. - Approved medicines go through clinical trials and federal review. - Research-grade peptides depend on the supplier’s own testing for quality. - Independent testing of unregulated products has found wrong doses, wrong amino-acid sequences, heavy metals, bacterial contamination and, in some cases, no active compound. - In late 2023, the FDA placed several research peptides, including BPC-157, CJC-1295, AOD-9604 and thymosin alpha-1, into the 503A Category 2 list for compounding concerns, citing immune reactions, impurities and missing human safety data, as reported by STAT News. - In April 2026, the FDA removed several of those compounds, including BPC-157 and CJC-1295, from Category 2 after their nominations were withdrawn. - That removal was not authorization to compound, and none of the compounds is FDA-approved. - Koi’s survey found that 75% of lab researchers cite sourcing quality as a top concern when buying peptide materials.

What's next: - The FDA’s Pharmacy Compounding Advisory Committee is scheduled to review the compounds on July 23 and 24, 2026. - Koi Peptides says it will continue selling products only for bench research, not for people or animals. - The company says each lot is checked with ISO/IEC 17025-accredited testing, including reverse-phase HPLC, mass spectrometry and LAL endotoxin testing. - Koi says each lot gets a Certificate of Analysis posted on the product page and traceable by lot number.

The bottom line: - Koi Peptides is using its industry report to frame peptides as a market split between heavily regulated drugs and a research supply chain where quality control remains the central issue.